REGENXBIO Inc.
RGNXUS売上高
$170M
百万USD
営業利益
$-161M
百万USD
純利益
$-194M
百万USD
ROE
-188.7%
最新FY
EPS
$-3.76
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $19M | $-50M | - |
| FY2021 | Q2 | $22M | $-58M | - |
| FY2021 | Q3 | $31M | $-58M | $-1.37 |
| FY2021 | FY | $470M | $128M | $2.91 |
| FY2022 | Q1 | $22M | $-77M | - |
| FY2022 | Q2 | $33M | $-68M | $-1.58 |
| FY2022 | Q3 | $27M | $-75M | $-1.75 |
| FY2022 | FY | $113M | $-280M | $-6.50 |
| FY2023 | Q1 | $19M | $-67M | $-1.53 |
| FY2023 | Q2 | $20M | $-72M | $-1.66 |
| FY2023 | Q3 | $29M | $-62M | $-1.41 |
| FY2023 | FY | $90M | $-263M | $-6.02 |
| FY2024 | Q1 | $16M | $-63M | $-1.38 |
| FY2024 | Q2 | $22M | $-53M | $-1.05 |
| FY2024 | Q3 | $24M | $-60M | $-1.17 |
| FY2024 | FY | $83M | $-227M | $-4.59 |
| FY2025 | Q1 | $89M | $6M | $0.12 |
| FY2025 | Q2 | $21M | $-71M | $-1.38 |
| FY2025 | Q3 | $30M | $-62M | $-1.20 |
| FY2025 | FY | $170M | $-194M | $-3.76 |
| FY2026 | Q1 | $6M | $-90M | $-1.72 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $219M | $35M | $155M | $470M | $113M | $90M | $83M | $170M |
| 営業利益 | $-65M | $-76M | $88M | $-149M | $-119M | $160M | $-263M | $-268M | $-233M | $-161M |
| 純利益 | $-63M | $-73M | $100M | $-95M | $-111M | $128M | $-280M | $-263M | $-227M | $-194M |
| 総資産 | $173M | $199M | $544M | $498M | $708M | $1.1B | $833M | $574M | $466M | $453M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $162M | $183M | $509M | $450M | $378M | $764M | $516M | $312M | $260M | $103M |
| 営業CF | - | - | $105M | $-108M | $-54M | $219M | $-207M | $-218M | $-173M | $-124M |
| EPS | - | - | $2.73 | $-2.58 | $-2.98 | $2.91 | $-6.50 | $-6.02 | $-4.59 | $-3.76 |
| BPS | $6.10 | $5.78 | $13.97 | $12.12 | $8.89 | $17.80 | $11.88 | $7.02 | $5.18 | $1.99 |
| ROE | -38.9% | -40.0% | 19.6% | -21.0% | -29.5% | 16.7% | -54.3% | -84.5% | -87.5% | -188.7% |